BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel) 2021;13:3034. [PMID: 34204509 DOI: 10.3390/cancers13123034] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Cejuela M, Vethencourt A, Pernas S. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Curr Oncol Rep 2022. [PMID: 36255603 DOI: 10.1007/s11912-022-01339-4] [Reference Citation Analysis]
2 Oya K, Shen LT, Maruo K, Matsusaka S. Plasma Exchange May Enhance Antitumor Effects by Removal of Soluble Programmed Death-Ligand 1 and Extracellular Vesicles: Preliminary Study. Biomedicines 2022;10:2483. [PMID: 36289745 DOI: 10.3390/biomedicines10102483] [Reference Citation Analysis]
3 Madureira AC. Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma – There’s room for Immune Checkpoint Blockage? Front Immunol 2022;13:955000. [DOI: 10.3389/fimmu.2022.955000] [Reference Citation Analysis]
4 Li S, Yi L, Wei X, Zhang J, Wang X, Jiang C, Yan Z, Song L, Yang B, Wei P, Gao X, Wang J, Zhang H, Zhang J. Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.971414] [Reference Citation Analysis]
5 Soltani-Zangbar MS, Parhizkar F, Abdollahi M, Shomali N, Aghebati-Maleki L, Shahmohammadi Farid S, Roshangar L, Mahmoodpoor A, Yousefi M. Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives. Cell Commun Signal 2022;20:131. [PMID: 36038915 DOI: 10.1186/s12964-022-00948-7] [Reference Citation Analysis]
6 Beserra DR, Alberca RW, Branco ACCC, Oliveira LM, de Souza Andrade MM, Gozzi-silva SC, Teixeira FME, Yendo TM, da Silva Duarte AJ, Sato MN, Xu B. Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/9764002] [Reference Citation Analysis]
7 R Bonam S, Hu H, Bayry J. Role of the PD-1 and PD-L1 axis in COVID-19. Future Microbiol 2022. [PMID: 35899493 DOI: 10.2217/fmb-2022-0103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Li X, Du H, Zhan S, Liu W, Wang Z, Lan J, Puyang L, Wan Y, Qu Q, Wang S, Yang Y, Wang Q, Xie F. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. Front Immunol 2022;13:830606. [DOI: 10.3389/fimmu.2022.830606] [Reference Citation Analysis]
9 Garajová I, Cavazzoni A, Verze M, Minari R, Pedrazzi G, Balsano R, Gelsomino F, Valle RD, Digiacomo G, Giovannetti E, Leonardi F. It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer. Life (Basel) 2022;12:960. [PMID: 35888050 DOI: 10.3390/life12070960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Razaghi A, Mansouri L, Brodin O, Björnstedt M, Lundahl J. Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial. Front Oncol 2022;12:906134. [PMID: 35720000 DOI: 10.3389/fonc.2022.906134] [Reference Citation Analysis]
11 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Front Immunol 2022;13:827921. [DOI: 10.3389/fimmu.2022.827921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Turiello R, Capone M, Morretta E, Monti MC, Madonna G, Azzaro R, Del Gaudio P, Simeone E, Sorrentino A, Ascierto PA, Morello S. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. J Immunother Cancer 2022;10:e004043. [PMID: 35273100 DOI: 10.1136/jitc-2021-004043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
15 Erol A. Importance of Efferocytosis in COVID-19 Mortality. IDR 2022;Volume 15:995-1007. [DOI: 10.2147/idr.s348639] [Reference Citation Analysis]
16 Xing Y, Liu J, Luo J, Ming T, Yang G, Sun S, Xu S, Li X, He E, Kong F, Yan S, Yang Y, Cai X. A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors. ACS Sens 2022;7:584-92. [PMID: 35060694 DOI: 10.1021/acssensors.1c02486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, Innominato PF, Bouchahda M, Adam R, Lévi F. Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers 2022;14:896. [DOI: 10.3390/cancers14040896] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Lu F, Dong Y, Li Q, Wang M, Tang M. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance. Computational and Mathematical Methods in Medicine 2022;2022:1-6. [DOI: 10.1155/2022/8375349] [Reference Citation Analysis]
19 Kummer MP, Ising C, Kummer C, Sarlus H, Griep A, Vieira-Saecker A, Schwartz S, Halle A, Brückner M, Händler K, Schultze JL, Beyer M, Latz E, Heneka MT. Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. EMBO J 2021;40:e108662. [PMID: 34825707 DOI: 10.15252/embj.2021108662] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
20 Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol 2021;6:eabf4034. [PMID: 34739340 DOI: 10.1126/sciimmunol.abf4034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Li B, Pu W, Weng L, Lyu P, Xu H, Zhang W, Ge L, Kwok HF, Wu Q. Aptamer‐functionalized Ti 3 C 2 ‐MXene Nanosheets with One‐step Potentiometric Detection of Programmed Death‐ligand 1. Electroanalysis 2022;34:2-7. [DOI: 10.1002/elan.202100438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Adorisio S, Cannarile L, Delfino DV, Ayroldi E. Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? Cells 2021;10:2333. [PMID: 34571982 DOI: 10.3390/cells10092333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]